Literature DB >> 17710087

Treatment of amiodarone-associated thyrotoxicosis.

Jayne A Franklyn1, Michael D Gammage.   

Abstract

BACKGROUND: A 75-year-old man had a myocardial infarction complicated by poor left ventricular function and non-sustained ventricular tachycardia. He began treatment with amiodarone and 12 months later developed symptoms of thyrotoxicosis. INVESTIGATIONS: Thyroid function tests after commencement of amiodarone revealed a high-normal level of free T4 and low-normal level of free T3 with a normal serum TSH. When symptoms of thyrotoxicosis developed, significant rises in T4 and T3 levels and suppression of TSH were observed. Thyroid autoantibodies were detected and thyroid ultrasonography revealed a small multinodular goiter. DIAGNOSIS: Amiodarone-induced thyrotoxicosis (AIT) with features consistent with both AIT type I (in which thyroid antibodies and nodular goiter are present) and AIT type II (which is not responsive to thionamide therapy and eventually leads to permanent hypothyroidism). MANAGEMENT: The patient continued to be treated with amiodarone. He commenced thionamide (carbimazole) therapy but failed to improve, even after a dose increase. Glucocorticoid (prednisolone) therapy was therefore added. Combination therapy was associated with gradual clinical and biochemical improvement. The patient became persistently hypothyroid after stopping thionamide and glucocorticoid therapy and was stabilized on long-term thyroxine replacement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710087     DOI: 10.1038/ncpendmet0592

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN: 1745-8366


  7 in total

1.  The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.

Authors:  L Tomisti; C Urbani; G Rossi; F Latrofa; C Sardella; L Manetti; I Lupi; C Marcocci; L Bartalena; O Curzio; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2016-01-13       Impact factor: 4.256

2.  Thyroid gland: use of glucocorticoids in amiodarone-induced thyrotoxicosis.

Authors:  Mark P J Vanderpump
Journal:  Nat Rev Endocrinol       Date:  2009-12       Impact factor: 43.330

Review 3.  Amiodarone and the thyroid: a 2012 update.

Authors:  F Bogazzi; L Tomisti; L Bartalena; F Aghini-Lombardi; E Martino
Journal:  J Endocrinol Invest       Date:  2012-03-19       Impact factor: 4.256

4.  Endoplasmic reticulum stress as a novel mechanism in amiodarone-induced destructive thyroiditis.

Authors:  Angela Lombardi; William Barlow Inabnet; Randall Owen; Kaitlyn Ellen Farenholtz; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

5.  Total thyroidectomy for medically refractory amiodarone-induced thyrotoxicosis.

Authors:  Ankit N Mehta; Raphaelle D Vallera; Chad R Tate; Rebecca A Sager; Brian J Welch
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-10

Review 6.  Thyrotoxic cardiac disease.

Authors:  Peter Dahl; Sara Danzi; Irwin Klein
Journal:  Curr Heart Fail Rep       Date:  2008-09

7.  A Case of Type 2 Amiodarone-Induced Thyrotoxicosis That Underwent Total Thyroidectomy under High-Dose Steroid Administration.

Authors:  Koshi Hashimoto; Masaki Ota; Tadanobu Irie; Daisuke Takata; Tadashi Nakajima; Yoshiaki Kaneko; Yuko Tanaka; Shunichi Matsumoto; Yasuyo Nakajima; Masahiko Kurabayashi; Tetsunari Oyama; Izumi Takeyoshi; Masatomo Mori; Masanobu Yamada
Journal:  Case Rep Endocrinol       Date:  2015-01-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.